A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke

Stroke

Volumn 42, Issue 7, 2011, Pages 2013-2018

  Kim, Anthony S ^a   Nguyen Huynh, Mai ^a   Johnston, S Claiborne ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute stroke; cost utility analysis; economics; endovascular treatment; interventional neuroradiology; thrombolysis; thrombolytic prescription

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ACUTE DISEASE; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN ANGIOGRAPHY; CASE REPORT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION TREE; EMERGENCY TREATMENT; HIDDEN MARKOV MODEL; HOSPITAL COST; HUMAN; LIFESPAN; MECHANICAL THROMBECTOMY; MEDICARE; MONTE CARLO METHOD; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; REIMBURSEMENT; SENSITIVITY ANALYSIS; SIMULATION; SYSTEMATIC REVIEW; VALIDATION PROCESS; VALIDATION STUDY;

AGED; CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); CEREBRAL ANGIOGRAPHY; COST-BENEFIT ANALYSIS; HUMANS; INFUSIONS, INTRAVENOUS; MARKOV CHAINS; MEDICARE; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; STROKE; THROMBECTOMY; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 79960028721     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.606889     Document Type: Article

References (29)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50: 883-890. (Pubitemid 28212810)
3. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke. 2007;38:967-973. (Pubitemid 46568460)
4. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36:1432-1438. (Pubitemid 40967507)
5. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282:2003-2011.
6. Patil CG, Long EF, Lansberg MG. Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke. J Neurosurg. 2009; 110:508-513.
7. Nguyen-Huynh MN, Johnston SC. Is Mechanical Clot Removal or Disruption a Cost-Effective Treatment for Acute Stroke? AJNR Am J Neuroradiol. 2011;32:244-249.
8. Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, et al. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008;3:130-137. (Pubitemid 351566847)
9. Mazighi M, Serfaty JM, Labreuche J, Laissy JP, Meseguer E, Lavallee PC, et al. Comparison of intravenous alteplase with a combined intravenous- endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol. 2009;8:802-809.
10. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008;39:1205-1212. (Pubitemid 351440692)
11. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
12. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
13. Kaufmann TJ, Huston J III, Mandrekar JN, Schleck CD, Thielen KR, Kallmes DF. Complications of diagnostic cerebral angiography: evaluation of 19,826 consecutive patients. Radiology. 2007;243:812-819. (Pubitemid 46799436)
14. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008; 39:1647-1652.
15. Saqqur M, Tsivgoulis G, Molina CA, Demchuk AM, Siddiqui M, Alvarez-Sabin J, et al. Symptomatic intracerebral hemorrhage and recanalization after IV rtPA: a multicenter study. Neurology. 2008;71: 1304-1312.
16. Ribo M, Alvarez-Sabín J, Montaner J, Romero F, Delgado P, Rubiera M, et al. Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke. 2006;37:1000-1004.
17. Williams D, Borer J, Braunwald E, Chesebro J, Cohen L, Dalen J, et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI Thrombolysis in Myocardial Infarction Trial. Circulation. 1986;73:338.
18. Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates. Department of Health and Human Services. Centers for Medicare & Medicaid Services. Federal Register. August 19, 2008;73:48433-49084.
19. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845. (Pubitemid 26001259)
20. Consumer Price Index: Medical Care Services 1936-2008. U.S. Bureau of Labor Statistics. http://www.bls.gov/spotlight/2009/health-care/data.htm#chart- cpi. Accessed May 19, 2011.
21. Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006;37:2751-2758. (Pubitemid 44929415)
22. Arias E. United States life tables, 2006. Natl Vital Stat Rep. 2006;581-40.
23. Strauss DJ, Shavelle RM, Anderson TW. Long-term survival of children and adolescents after traumatic brain injury. Arch Phys Med Rehabil. 1998;79:1095-1100. (Pubitemid 28419318)
24. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ. 1992;146: 473-481.
25. Lee KY, Han SW, Kim SH, Nam HS, Ahn SW, Kim DJ, et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre-and post-thrombolytic angiography in acute ischemic stroke patients. Stroke. 2007;38:192-193. (Pubitemid 46035627)
26. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007;38:2279-2283. (Pubitemid 47457569)
27. Smith WS. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. AJNR Am J Neuroradiol. 2006;27:1177-1182. (Pubitemid 44897621)
28. Cintas P, Le Traon AP, Larrue V. High rate of recanalization of middle cerebral artery occlusion during 2-MHz transcranial color-coded Doppler continuous monitoring without thrombolytic drug. Stroke. 2002;33: 626-628. (Pubitemid 34123418)
29. Maudlin PD, Simpson KN, Palesch YY, Spilker JS, Hill MD, Kharti P, et al. Design of the economic evaluation for the Interventional Management of Stroke (III) trial. Int J Stroke. 2008;3:138-144. (Pubitemid 351566848)